{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:52:28Z","timestamp":1790146348679,"version":"4.0.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/md.0b013e3181f2caef","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T11:01:57Z","timestamp":1283943717000},"page":"308-318","source":"Crossref","is-referenced-by-count":144,"title":["Late-Onset Neutropenia After Rituximab Treatment"],"prefix":"10.1097","volume":"89","author":[{"given":"Ofir","family":"Wolach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Bairey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Lahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210309","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1378\/chest.120.5.1695","article-title":"Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data.","volume":"120","author":"Azoulay","year":"2001","journal-title":"Chest"},{"key":"R3-5-20210309","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.11312","article-title":"Rituximab for the treatment of autoimmune cytopenias.","volume":"92","author":"Berentsen","year":"2007","journal-title":"Haematologica"},{"key":"R4-5-20210309","first-page":"361","article-title":"High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.","volume":"89","author":"Cairoli","year":"2004","journal-title":"Haematologica"},{"key":"R5-5-20210309","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/10428190500473113","article-title":"Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments.","volume":"47","author":"Cattaneo","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R6-5-20210309","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy.","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br J Haematol"},{"key":"R7-5-20210309","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00277-008-0455-2","article-title":"Late-onset neutropenia following viral bone marrow depression after rituximab therapy.","volume":"87","author":"Christopeit","year":"2008","journal-title":"Ann Hematol"},{"key":"R8-5-20210309","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H","article-title":"CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes.","volume":"43","author":"Coakley","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R9-5-20210309","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma.","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"issue":"Suppl 1","key":"R10-5-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200262001-00001","article-title":"Colony-stimulating factors for the management of neutropenia in cancer patients.","volume":"62","author":"Dale","year":"2002","journal-title":"Drugs"},{"key":"R11-5-20210309","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"R12-5-20210309","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"key":"R13-5-20210309","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","article-title":"Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.","volume":"6","author":"Flinn","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-5-20210309","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1532\/IJH97.05105","article-title":"Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma.","volume":"84","author":"Fukuno","year":"2006","journal-title":"Int J Hematol"},{"key":"R16-5-20210309","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.","volume":"156","author":"Goh","year":"2007","journal-title":"Br J Dermatol"},{"key":"R17-5-20210309","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2169\/internalmedicine.48.1368","article-title":"Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.","volume":"48","author":"Hirayama","year":"2009","journal-title":"Intern Med"},{"key":"R18-5-20210309","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.","volume":"103","author":"Horwitz","year":"2004","journal-title":"Blood"},{"key":"R19-5-20210309","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","article-title":"A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"60","author":"Jones","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R22-5-20210309","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera).","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"R23-5-20210309","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2006.05.002","article-title":"Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment.","volume":"17","author":"Klepfish","year":"2006","journal-title":"Eur J Intern Med"},{"key":"R24-5-20210309","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/ajh.21420","article-title":"Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.","volume":"84","author":"Lai","year":"2009","journal-title":"Am J Hematol"},{"key":"R25-5-20210309","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1704467","article-title":"Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.","volume":"33","author":"Lemieux","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"R26-5-20210309","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-5231(03)00123-0","article-title":"Chemotherapy-induced lung disease.","volume":"25","author":"Limper","year":"2004","journal-title":"Clin Chest Med"},{"key":"R27-5-20210309","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jbspin.2008.02.001","article-title":"Organizing pneumonia associated with rituximab: challenges raised by establishing causality.","volume":"75","author":"Liote","year":"2008","journal-title":"Joint Bone Spine"},{"key":"R29-5-20210309","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by fas ligand.","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"key":"R30-5-20210309","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1164\/ajrccm.154.6.8970380","article-title":"Lung toxicity associated with cyclophosphamide use. Two distinct patterns.","volume":"154","author":"Malik","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"R31-5-20210309","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R32-5-20210309","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190600649349","article-title":"Late-onset neutropenia following rituximab.","volume":"47","author":"McLaughlin","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R33-5-20210309","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R34-5-20210309","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"key":"R35-5-20210309","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-05-1532","article-title":"Rituximab-associated immune myelopathy.","volume":"102","author":"Papadaki","year":"2003","journal-title":"Blood"},{"key":"R36-5-20210309","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases.","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk Res"},{"key":"R37-5-20210309","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/10428190902934944","article-title":"The late adverse events of rituximab therapy-rare but there!","volume":"50","author":"Ram","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R38-5-20210309","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R39-5-20210309","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","article-title":"Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases.","volume":"157","author":"Rios-Fernandez","year":"2007","journal-title":"Br J Dermatol"},{"key":"R40-5-20210309","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1182\/blood-2003-02-0450","article-title":"Agranulocytosis unresponsive to growth factors following rituximab in vivo purging.","volume":"101","author":"Rose","year":"2003","journal-title":"Blood"},{"key":"R41-5-20210309","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1012500524758","article-title":"Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG.","volume":"12","author":"Saikia","year":"2001","journal-title":"Ann Oncol"},{"key":"R42-5-20210309","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","article-title":"Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.","volume":"122","author":"Shimoni","year":"2003","journal-title":"Br J Haematol"},{"key":"R43-5-20210309","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","article-title":"Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma.","volume":"38","author":"Shortt","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"R44-5-20210309","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","article-title":"Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia.","volume":"22","author":"Stamatopoulos","year":"2008","journal-title":"Leukemia"},{"key":"R45-5-20210309","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1345\/aph.1G311","article-title":"Rituximab treatment of refractory rheumatoid arthritis.","volume":"39","author":"Summers","year":"2005","journal-title":"Ann Pharmacother"},{"key":"R46-5-20210309","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"key":"R47-5-20210309","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-008-9049-z","article-title":"Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.","volume":"25","author":"Tesfa","year":"2008","journal-title":"Med Oncol"},{"key":"R48-5-20210309","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2005.05.006","article-title":"Rituximab: a promising therapy in systemic lupus erythematosus.","volume":"5","author":"Thatayatikom","year":"2006","journal-title":"Autoimmun Rev"},{"key":"R49-5-20210309","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1701944","article-title":"Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.","volume":"24","author":"Tsai","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R50-5-20210309","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"R51-5-20210309","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab.","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"key":"R52-5-20210309","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease.","volume":"82","author":"Wagner","year":"2007","journal-title":"Am J Hematol"},{"key":"R53-5-20210309","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2009.25.0274","article-title":"Immunoglobulin G Fc receptor FcgammaRIIIa 158 V\/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.","volume":"28","author":"Weng","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0b013e3181f2caef","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:33:15Z","timestamp":1620963195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201009000-00005"}},"subtitle":["Case Series and Comprehensive Review of the Literature"],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e3181f2caef","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}